Home AIM ImmunoTech AIM ImmunoTech Videos Hemispherx Biopharma (HEB) Update: 1st Patient Treaded In Phase 2 Clinical Trial

Hemispherx Biopharma (HEB) Update: 1st Patient Treaded In Phase 2 Clinical Trial

29
0

In this episode of CEO Roadshow, we’re joined again by Mr. Thomas Equels, CEO of Hemispherx Biopharma, an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology.

They trade on the under ticker HEB.

In this interview, Mr. Equels discusses the ongoing clinical trials the company is currently conducting with their pipeline candidate, Ampligen.

Please see the following press release regarding the Ampligen Pancreatic Cancer Program.

Hemispherx Biopharma Announces IRB Approval of Clinical Study in Metastatic Triple-Negative Breast Cancer in Collaboration with Roswell Park Comprehensive Cancer Center

http://MedInvestNews.com/hemispherx-biopharma-announces-significant-progress-in-its-ampligen-pancreatic-cancer-program-and-multiple-ampligencheckpoint-blockade-immuno-oncology-programs/

Forward-Looking Statements

This MedInvestNews.COM video interview contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include failure to meet schedule or performance requirements of the Company’s contracts, the Company’s ability to raise sufficient development and working capital, the Company’s liquidity position, the Company’s ability to obtain new contracts, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur as planned or at all.

Contact MedInvestNews.COM

Mike Elliott
MikeElliott@MedInvestNews.COM

Disclaimer

CEORoadshow.com is committed to providing our readers with useful information on publicly traded companies. CEORoadshow.com sometimes contracts with third parties or publicly traded companies and receives compensation from them in the form of cash and sometimes restricted securities as payment for publishing information and opinions about the company and the trading market for their securities. CEORoadshow.com content should not be considered to be independent publications concerning the company.

Neither CEOROADSHOW.COM or any of its principals currently own or plan to own within 72 hours of publication any shares of the stocks mentioned in this video. For a full disclaimer please visit, CEOROADSHOW.COM/disclaimer.

CEOROADSHOW content and productions are based on data obtained from sources we believe to be reliable but are not guaranteed as to the accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in CEOROADSHOW content and productions, or other investor relations materials and presentations are subject to change. Neither CEOROADSHOW nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. All data and information are provided for informational or entertainment purposes only. CEOROADSHOW is not a registered broker-dealer or a registered investment advisor.

LEAVE A REPLY

Please enter your comment!
Please enter your name here